Zusammenfassung
Neben Schmerzen können Palliativpatienten unter einer Reihe anderer, ebenso belastender Beschwerden leiden, zu denen auch die Atemnot zählt. Atemnot ist zuerst ein subjektives Gefühl, dessen Schwere somit nur Patienten selbst beurteilen können. Eine sorgfältige Ursachensuche ist angezeigt. Ebenso können Übelkeit und Erbrechen verschiedene Ursachen haben, die etwa im Verdauungstrakt selbst liegen oder durch Stoffwechselentgleisungen ausgelöst werden, durch cerebrale Veränderungen hervorgerufen werden, oder nicht selten einfach als Nebenwirkungen von Medikamenten entstehen. Ein häufiges Problem stellt die intestinale Obstipation und/oder Obstruktion dar, zu deren Behandlung individuell angepasste Behandlungskonzepte existieren. Intestinale Obstruktion und Hyperkalzämie können zu einer schweren Symptomlast führen, die differenziert anzugehen ist. Häufig und sehr belastend für Patienten, Angehörige und Betreuungsteam ist das terminale Delir, für dessen Behandlung mehrere Medikamente zur Verfügung stehen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Adams L, Chronos N, Lane G, Guz A (1985) The measurement of breathlessness induced in normal subjects: validity of two scaling techniques. Clin Sci (Lond) 69:7–16
Akechi T, UchitomiY OH (1996) Usage of haloperidol for delirium in cancer patients. Support Cancer Care 4:390–392
Allard P, Lamontagne C, Bernard P, Trenblay C (1999) How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients. J Pain Symptom Manage 17:256–265
Alt-Epping B, Sitte T, Nauck F, Radbruch L (2010) Sedierung in der Palliativmedizin. Z Palliativmed 11:112–122
American Psychiatric Association (1994) Diagnostic and statistical Manual of Mental disorders. APA, Washington DC
Anti M, Pignataro G, Armuzzi A et al (1998) Water supplementation enhances the effect of high fiber diet on stool frequency and laxative consumption in adult patients with functional constipation. Hepatogastroenterology 45:727
AWMF (2013) S2k-Leitlinie Chronische Obstipation, aktueller Stand: 02/2013. Register-Nr. 021/019
AWMF (2015) S3-Leitlinie Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung, Version 1.0 – Mai 2015. Register-Nr: 128/001OL
Bausewein C, Booth S, Gysels M, Kühnbach R, Higginson IJ (2010) Effectiveness of a hand-held fan for breathlessness: a randomised phase II trial. BMC Palliat Care 9:12. https://doi.org/10.1186/1472-684X-9-22
Body JJ, Bartl R, Bruckhardt P et al (1998) Current use of bisphosphonates in oncology. J Clin Oncol 16(12):3890–3899
Borg GA (1982) Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14:377–781
Breitbart W, Marotty R, Platt M (1996) A double-blind comparison trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 153:231–237
Breitbart W (2001) Diagnosis and management of delirium in the terminally ill. In: Portenoy, BE (Hrsg) Topics in Palliative care, Vol 5. Oxford University Press, New York, S 303–321
Bruera E, Fainsinger R, Miller M, Kuehn N (1992) The assessment of pain intensity in patients with cognitive failure. J Pain Symp Man 7(5):267–270
Bruera E, Hui D, Dalal S, Torres-Vigil I et al (2013) Parenteral hydration in patients with advanced cancer: a multicenter, double-blind, placebo-controlled randomized trial. J Clin Oncol 31(1):111–118
Chua TP, Harrington D, Ponikowski P et al (1997) Effects of dihydrocodein on chemosensitivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 29:147–152
Currow DC, Coughlan M, Fardell B, Cooney NJ (1997) Use of ondasentron in palliative medicine. J Pain Symptom Manage 13:302–307
Currow DC, Quinn S, Agar M et al (2015) Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. J Pain Symptom Manage 49(5):814–821
Davis K, Attie M (1991) Management of severe hypercalcaemia. Crit Care Clin 7:175–190
Drossman DA (2006) Rome III: The functional gastrointestinal disorders, 3. Aufl. Degnon Associates Inc, McLean, VA
Drossman et al (1990) Identificationof subgroups of functiomal gastrointestinal disorders. Gatroenterol Int 3:159–172
Emanuel EJ, Fairclough DL, Slutsman J, Emanuel LL (2000) Understanding economic and other burdens of terminal illness: experience of patients and their caregivers. Ann Intern Med 132:451–459
Evans KC, Bahnzett RB, Adams L (2002) BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol 88:1500–1511
Fainsinger R, McEachern T, Hanson J (1991) Symptome control during the last week of life in a palliative care unit. J Palliative Care 7:5–11
Fallon B (1998) Nausea and vomiting unrelated to case treatment. In: Berger AM, Portenoy RK, Weissman DE (Hrsg) Principle and practice of supportive oncology. Lippincott Williams and Wilkins, Philadelphia, S 179–190
Fernandez F, Levy J, Mansell P (1989) Management of delirium in terminally ill AIDS patients. Int J Psychiat Med 19:165–172
Feuer DJ, Broadley KE (1999) Systematic review of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers. Ann Oncol 10:1035–1040
Gaginella TS, Bris P (1978) Laxatives: an update on the mechanism of action. Life Sci 23:1001–1010
George J, Crawford D, Lewis T et al (1990) Percutaneous endoscopic gastrostomy: a tow year experience. Med J Aust 152:17–20
Glare P, Peirera G, Krsitjanson LJ et al (2001) Systematic review of the efficacy of antiemetic in the treatment of nausea in patients with far-advanced cancer. Support Care Cancer 12:432–440
Gonzales-Rosales F, Walsh D (1997) Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol. J Pain Sympton Manage 14(5):311–314
Hardy J, Daly S, McQuade B et al (2002) A double-blind, randomized parallel group, multinational, multi-centre study comparing ondansetron 24 mg p. o. with placebo and metoclopramide 10 mf tds p. o. in the treatment of opioid induced nausea and emesis in cancer patients. Support Care Cancer 10:331–336
Heath DA (1989) Hypercalcemia of malignancy. BMJ 298:1468–1469
Hestermann U, Backenstrass M, Gekle I et al (2009) Validation of a German version of the Confusion Assessment Method for delirium detection in a sample of acute geriatric patients with a high prevalence of dementia. Psychopathology 42(4):270–276
McCarthyM HI (1989) Measuring symptoms in terminal cancer: are pain and dyspnea controlled? J R Soc Med 82:264–266
Holmes S (1989) Use of a modified symptom distress scale in assessment of the cancer patient. Int J Nurs Stud 26:69–7932
Inouye B, Bogardus S Jr, Charpentier P et al (1999) A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med 340(9):669–676
Johnson MJ, McDonagh TA, Harkness A et al (2001) Morphine for the relief of breathlessness in patients with chronic heart failure-a pilot study. Eur J Heart Fail 4:753–756
Kovacs C, MacDonald S, Chik C, Bruera E (1995) Hypercalcemia of malignancy in the palliative care patient: a treatment strategy. J Pain Symptom Manage 10:224–232
Lawlor P, Gagnon B, Mancini I et al (2001) The occurrence, causes and outcome of delirium in advanced cancer patients: a prospective study. Arch Int Med 160:786–794
Leupoldt A, Dahme B (2005) Cortical substrates for the perception of dyspnea. Chest 128(1):345–354
Light RW, Muro JR, Sato RI et al (1989) Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 139:126–133
Lowler P (2002) Delirium and dehydration: Some fluid for thought? Support Care Cancer 195:835–839
MacKintosh D (2016) Olanzapine in the management of difficult to control nausea and vomiting in a palliative care population: A case series. J Palliat Med 19:87–90
Major P (2001) Use of zeolendroic acid, a novel, highly potent bisphosphonate, for treatment of hypercalcemia of malignancy. Oncologist 7:481–491
Manning HL, Schwartzstein RM (1995) Pathophysiology of dyspnea. N Engl J Med 333:1547–1553
Massie M, Holland J, Glass E (1983) Delirium in terminally ill cancer patients. Am J Psychiatry 140:1048–1050
Mazzocatto C, Buclin T, Rapin CH (1999) The effects of morphine on dyspnea on ventilator function in elderly patients with advanced cancer: a randomized double-blind controlled trial. Annal Oncol 10:1511–1014
Menza M, Murray G, Holmes V (1988) Controlled study of extrapyramidal reactions in the management of delirious medically ill patients: Intravenous Haldol versus Haldol plus benzodiazepines. Heart Lung 17:2318–2341
Mercadante S, Avola G, Maddaloni S et al (1996) Octreotide prevents the pathological alterations of bowl obstruction in cancer patients. Support Care Cancer 4:393–394
Mercadante S, De Conno F, Ripamonti C (1995) Propofol in terminal care. J Pain Symptom Manage 10:639–642
Mercadante S, Spoldi CA et al (1993) Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med 7:295–299
Morita T, Hyodo I, Yoshimi T et al (2004) Incidence and underlying etiologies of bronchial secretion in terminally ill cancer patients: a multicenter, prospective, observational study. J Pain symptom Manage 27:533–539
Morita T, Tsunoda J, Inoue S et al (1999) Perception and decision-making on rehydration of terminally ill cancer patients and family members. Am J Hosp Palliat Care 16:509–516
Moyle J (1995) The use of propofol in palliative medicine. J Pain Symptom Manage 10:643–646
Muers MF, Round CE (1993) Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organization Thoracic Group. Thorax 48:339–343
Nash Smyth E, Conti I, Wooldridge JE et al (2015) Frequency of skeletal-related events and associated health care resource use and costs in US patients with multiple myeloma. J Med Econ 15:1–26
Nellgard P, Bojo L, Cassuto J (1995) Importance of vasoactive intestinal peptide and somatostatin for fluid loss in small bowl obstruction. Scand J Gastroenterol 30:464–469
Nelville R, Fielding P, Cambria RP, Modlin I (1991) Vascular responsiveness in obstructive gut. Dis Colon Rectum 4:229–235
Oliver D (1985) The use of methotrimeprazine in terminal care. BrJ Clin Pract 39:339–340
Passik S, Cooper M (1999) Complicated delirium in cancer patients successfully treated with olanzapine. J Pain Symptom Manage 7:219–223
Patel S, Lyons A, Hosking D (1993) Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use. Drugs 46:594–617
Pictus D, Marx MV, Weyman PJ (1988) Chronic intestinal obstruction: value of percutaneous gastrostomy tube placement. Am J Radiol 150:295–297
Reuben DB, Mor V (1986) Dyspnea in terminally ill cancer patients. Chest 89:234–326
Reynolds JC, Putnam PE (1992) Prokinetic agents. Gastroenterol Clin North Am 21:567–596
Ripamonti C, Panzeri C, Groff L et al (2001) The role of somatostatin and octreotide in bowl obstruction: pre-clinical and clinical results. Tumori 87:1–9
Sarhill N, Walsh D, Nelson K, Davis M (2001) Evaluation and treatment of cancer related fluid deficits: volume depletion or dehydration. Support Care Cancer 9:408–419
Schwartz T, Massand P (2001) The role of atypical antipsychotics in the treatment of delirium. Psychosomatics 43:171
Sipahimalami A, Sime RM, Massand P (1997) Treatment of delirium with risperdon. In J Geriatric Psychopharmacol 1:24–26
Srivastava M, Brito-Dellan N, Davis MP et al (2003) Olanzapine a s an antiemetic in refractory nausea and vomiting in advanced cancer. J Palliat Med 6:251–255
Stark RD, Gambles SA, Lewis JA (1981) Methods to access breathlessness in healthy subjects: a critical evaluation and application to analyze the acute effects of diazepam and promethazin on breathlessness induced by exercise or by exposure to raised levels of carbon dioxide. Clin Sci (Lond) 61:429–439
Stiefel F, Kornblith A, Holland J, Coyle N, Breitbart W, Weaver S, Portenoy R (1994) Delirium as a contributing factor to ›crescendo‹ pain: Three case reports. J Pain Symptom Manage 9:44–47
Thomas JR, von Guten CH (2006) Dyspnea. In: Bruera E, Higgins IJ, Ripamonti C, von Guten CH (eds) Textbook of palliative medicine. Oxford University Press, S 655–662
Twycross R, Back I (1998) Nausea and vomiting in advanced cancer. Eur J Palliat Care 5:39–45
Ventafridda V, Ripamonti C, Caraceni A et al (1990a) The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori 76:389–393
Ventafridda V, Ripamonti C, DeConno F (1990b) Symptom prevalence and control during cancer patients´ last days of life. J Palliat Care 6:7–11
Wald A (2000) Constipation. Med Clin North Am 84:1231
Williams SG, Wright DJ, Marshall P et al (2002) Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart 88:1085–1086
Woodcock AA, Gross ER, Geddes DM (1981) Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. Br Med J (Clin Re Ed) 281:343–346
Zebraski SE, Kochenash SM, Raffa RB (2000) Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci 66:2221–2231
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature
About this chapter
Cite this chapter
Watzke, H. (2023). Symptomkontrolle. In: Husebø, S., Mathis, G., Masel, E.K. (eds) Palliativmedizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-65768-3_5
Download citation
DOI: https://doi.org/10.1007/978-3-662-65768-3_5
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-65767-6
Online ISBN: 978-3-662-65768-3
eBook Packages: Medicine (German Language)